Physician profile
Cesar Chavarria
NPI 1609803212
$1,419.79
in general payments reported to CMS, 2019-2025
12 companies · $125 in 2025
The $125 reported for 2025 was more than what a typical Pediatric Critical Care Medicine provider received nationally (typical 2025 total: $71.68).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.13 · 2020: $35.61 · 2021: $86.00 · 2022: $408 · 2023: $354 · 2024: $335 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731 · Education: $83.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.49 |
| Education | $83.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $822.59 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $179.50 | 2022-2023 | |
| Sobi, INC | $91.07 | 2019-2023 | |
| Novo Nordisk INC | $71.93 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $58.04 | 2022-2024 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $44.06 | 2022-2024 | Nucala |
| Regeneron Healthcare Solutions, INC. | $36.86 | 2024 | Dupixent |
| Insmed, INC. | $30.88 | 2025 | Brinsupri |
| Sanofi Pasteur INC. | $28.89 | 2024 | |
| Lifescan, INC. | $21.62 | 2019 | |
| Advanced Respiratory, INC | $20.32 | 2021 | |
| Amgen INC. | $14.03 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Chavarria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.